ATE537144T1 - Nitrierte heterocyclische verbindungen als endothelinrezeptorantagonisten - Google Patents

Nitrierte heterocyclische verbindungen als endothelinrezeptorantagonisten

Info

Publication number: ATE537144T1
Authority: AT; Austria
Prior art keywords: nitrited; receptor antagonists; heterocyclic compounds; endothelin receptor; endothelin
Prior art date: 2006-05-29

Application number

AT07729447T

Other languages

English (en)

Inventor

Nicoletta Almirante

Stefano Biondi

Ennio Ongini

Original Assignee

Nicox Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-29

Filing date

2007-05-23

Publication date

2011-12-15

2007-05-23 Application filed by Nicox Sa filed Critical Nicox Sa

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE537144T1 publication Critical patent/ATE537144T1/de

Links

229940118365 Endothelin receptor antagonist Drugs 0.000 title 1
239000002308 endothelin receptor antagonist Substances 0.000 title 1
150000002391 heterocyclic compounds Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

AT07729447T 2006-05-29 2007-05-23 Nitrierte heterocyclische verbindungen als endothelinrezeptorantagonisten ATE537144T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06114617		2006-05-29
PCT/EP2007/055012 WO2007137980A1 (en)	2006-05-29	2007-05-23	Nitrated heterocyclic compounds as endothelin receptor antagonist

Publications (1)

Publication Number	Publication Date
ATE537144T1 true ATE537144T1 (de)	2011-12-15

Family

ID=38255421

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT07729447T ATE537144T1 (de)	2006-05-29	2007-05-23	Nitrierte heterocyclische verbindungen als endothelinrezeptorantagonisten

Country Status (16)

Country	Link
US (1)	US20090263472A1 (de)
EP (1)	EP2021324B1 (de)
JP (1)	JP2009538862A (de)
KR (1)	KR20090020559A (de)
CN (1)	CN101454283A (de)
AR (1)	AR061598A1 (de)
AT (1)	ATE537144T1 (de)
AU (1)	AU2007267209A1 (de)
BR (1)	BRPI0711315A2 (de)
CA (1)	CA2652636A1 (de)
MX (1)	MX2008015289A (de)
NO (1)	NO20085375L (de)
NZ (1)	NZ571820A (de)
RU (1)	RU2008150440A (de)
WO (1)	WO2007137980A1 (de)
ZA (1)	ZA200808766B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR073259A1 (es) *	2008-07-29	2010-10-28	Merck & Co Inc	Derivados de furosemida utiles como diureticos
EP2398761A4 (de) *	2009-02-18	2015-11-04	Bezwada Biomedical Llc	Verzögerte freisetzung von stickoxid und wirkstoffen aus funktionalisierten makromeren und oligomeren
US20120283190A1 (en) *	2009-12-09	2012-11-08	Institut National de la Santé et de la Recherche Medicale (INSERM)	Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
WO2012152438A1 (en) *	2011-05-11	2012-11-15	Nicox S.A.	Process for the preparation of nitrate acid ester of organic compounds
CA2926382C (en) *	2013-10-18	2020-06-02	Attoquant Diagnostics Gmbh	Method for diagnosis of primary hyperaldosteronism
CN118772120A (zh) *	2021-09-03	2024-10-15	深圳信立泰药业股份有限公司	一种内皮素a(eta)受体拮抗剂化合物及其制备方法和医药用途
CN119350280A (zh) *	2021-11-18	2025-01-24	广州楷石医药有限公司	一种氧化氮供体型贝前列素类衍生物及其药物组合物和用途
CN115959996B (zh) *	2022-01-28	2025-02-18	上海众强药业有限公司	No供体化合物及其药物组合物和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2195002T3 (es) *	1995-08-02	2003-12-01	Smithkline Beecham Corp	Antagonistas de los receptores de la endotelina.
CA2391818A1 (en)	1996-03-13	1997-09-18	Queen's University At Kingston	Antagonism of endothelin actions
ID25620A (id) *	1997-09-04	2000-10-19	Basf Ag	Turunan-turunan asam karboksilat baru, pembuatannya dan penggunaannya sebagai campuran reseptor antagonis et a/et b
TWI284642B (en)	1999-01-18	2007-08-01	Hoffmann La Roche	Novel heterocyclic sulfonamides
AU780261B2 (en)	1999-10-29	2005-03-10	Nitromed, Inc.	Methods of treating vascular diseases characterized by nitric oxide insufficiency
JP2007504135A (ja)	2003-08-28	2007-03-01	ニトロメッドインコーポレーティッド	ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法

2007
- 2007-05-23 JP JP2009512550A patent/JP2009538862A/ja not_active Withdrawn
- 2007-05-23 CA CA002652636A patent/CA2652636A1/en not_active Abandoned
- 2007-05-23 US US12/300,026 patent/US20090263472A1/en not_active Abandoned
- 2007-05-23 KR KR1020087026471A patent/KR20090020559A/ko not_active Withdrawn
- 2007-05-23 WO PCT/EP2007/055012 patent/WO2007137980A1/en not_active Ceased
- 2007-05-23 AU AU2007267209A patent/AU2007267209A1/en not_active Abandoned
- 2007-05-23 MX MX2008015289A patent/MX2008015289A/es active IP Right Grant
- 2007-05-23 NZ NZ571820A patent/NZ571820A/en not_active IP Right Cessation
- 2007-05-23 EP EP07729447A patent/EP2021324B1/de active Active
- 2007-05-23 BR BRPI0711315-3A patent/BRPI0711315A2/pt not_active IP Right Cessation
- 2007-05-23 AT AT07729447T patent/ATE537144T1/de active
- 2007-05-23 CN CNA2007800199691A patent/CN101454283A/zh active Pending
- 2007-05-23 RU RU2008150440/04A patent/RU2008150440A/ru not_active Application Discontinuation
- 2007-05-29 AR ARP070102313A patent/AR061598A1/es unknown
2008
- 2008-10-14 ZA ZA200808766A patent/ZA200808766B/xx unknown
- 2008-12-23 NO NO20085375A patent/NO20085375L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ZA200808766B (en)	2010-01-27
WO2007137980A1 (en)	2007-12-06
AR061598A1 (es)	2008-09-10
CA2652636A1 (en)	2007-12-06
CN101454283A (zh)	2009-06-10
KR20090020559A (ko)	2009-02-26
US20090263472A1 (en)	2009-10-22
NZ571820A (en)	2010-09-30
BRPI0711315A2 (pt)	2011-11-29
NO20085375L (no)	2009-02-25
JP2009538862A (ja)	2009-11-12
RU2008150440A (ru)	2010-07-20
AU2007267209A1 (en)	2007-12-06
MX2008015289A (es)	2008-12-12
EP2021324B1 (de)	2011-12-14
EP2021324A1 (de)	2009-02-11

Publication	Publication Date	Title
ATE481405T1 (de)	2010-10-15	Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
ATE540942T1 (de)	2012-01-15	Imidazolderivate als ccr2-rezeptor-antagonisten
ATE555111T1 (de)	2012-05-15	Chinuclidinol-derivate als muscarinrezeptor- antagonisten
DE602006015607D1 (de)	2010-09-02	Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE505467T1 (de)	2011-04-15	2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
ATE537151T1 (de)	2011-12-15	Pyrazolinverbindungen als mineralocorticoidrezeptorantagonisten
IL195110A0 (en)	2009-09-22	Substituted spirocyclic cgrp receptor antagonists
HRP20151108T1 (xx)	2015-11-20	Antagonisti nogo-receptora
BRPI0910118A2 (pt)	2015-12-29	antagonistas de receptores do glucagon
DK2009992T3 (da)	2012-08-13	Il-8 receptor-antagonister
ATE509928T1 (de)	2011-06-15	8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
DE602008003015D1 (de)	2010-11-25	Heterocyclische spiroverbindungen
DK2081951T3 (da)	2010-08-09	Progesteron-receptorantagonister
NL1028624A1 (nl)	2005-10-03	Alfa-aryl- of -heteroarylmethyl-bèta-piperidinopropaan-zuurverbindingen als ORL1-receptorantagonisten.
BRPI0817835A2 (pt)	2015-03-31	Antagonistas cgrp
ATE533744T1 (de)	2011-12-15	N-benzoypyrrolidin-3-ylamine als histamin-3 antagonisten
ATE519738T1 (de)	2011-08-15	Pyrrolidinarylether als nk3-rezeptorantagonisten
ATE517100T1 (de)	2011-08-15	Pyrrolidinarylether als nk3-rezeptorantagonisten
EP2254413A4 (de)	2011-10-26	Imidazobenzazepin-cgrp-rezeptorantagonisten
ATE477243T1 (de)	2010-08-15	2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
ATE537149T1 (de)	2011-12-15	Sulfonyl-pyrazolinyl-1-carboxamidinderivate als 5-ht6-antagonisten
HRP20160950T1 (hr)	2016-10-07	Polimorfi antagonista mglur5 receptora
IL195807A0 (en)	2009-09-01	Cgrp receptor antagonists
ATE537144T1 (de)	2011-12-15	Nitrierte heterocyclische verbindungen als endothelinrezeptorantagonisten
ATE421511T1 (de)	2009-02-15	Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors